TEVA : Analysis & Opinions

  1. Teva to Market Medical Marijuana Inhaler in Israel

    November 28, 2016
    Teva has partnered with Syqe to market a medical weed device similar to an asthma inhaler. It could help solve the dosage ...
  2. Drug Makers Sued for Price Collusion (NVS, TEVA)

    November 20, 2016
    Novartis, Teva, Akorn and other drug makers are being sued by NYPD unions for alleged price collusion on their skin creams.
  3. Teva Posts 3Q Profit Amid Bribery Charges (TEVA)

    November 16, 2016
    Teva posted a 3Q profit of $412 million amid revelations it will pay $520 million to settle bribery charges.
  4. Teva to Pay $520M in DOJ, SEC Bribery Case (TEVA)

    November 16, 2016
    Teva will pay $520 million to settle claims it bribed foreign countries to boost drug sales.
  5. Allergan Initiates Dividend, Boosts Share Buybacks

    November 3, 2016
    Busy pharmaceutical player Allergan (NYSE: AGN) has taken on an additional burden -- it will start to pay a dividend to ...
  6. Teva, IBM Expand Drug Repurposing Plan (TEVA, IBM)

    October 27, 2016
    Teva and IBM expanded their disease management and drug repurposing alliance.
  7. Teva’s Banned Hungarian Plant Warned by FDA (TEVA)

    October 20, 2016
    Teva's manufacturing plant in Gödöllő, Hungary, received an FDA warning letter for deficient operations, laboratory controls, ...
  8. FDA Holds Regeneron, Teva Pain Study (REGN, TEVA)

    October 18, 2016
    The FDA put Regeneron and Teva's joint study for the pain drug fasinumab on clinical hold, citing safety concerns.
  9. Teva, Celltion Enter $160M Biosimilar Deal (TEVA)

    October 14, 2016
    Teva Pharmaceutical will market Celltrion's biosimilar drugs, Truxima and Herzuma, in the United States and Canada under ...
  10. Teva Launches Generic Version of Beyaz (TEVA)

    October 14, 2016
    Teva Pharmaceutical rolled out Rajani, an oral contraceptive that's the generic version of Bayer's Beyaz birth control pill.
  11. Regeneron to Collaborate With Teva for Fasinumab Drug (REGN, ...

    September 20, 2016
    Regeneron will get a global commercialization opportunity with Teva for its innovative chronic pain drug having a large global ...
  12. Is Mylan The Next Valeant Trade? (MYL, VRX)

    September 2, 2016
    Mylan is caught in a political firestorm after EpiPen price increases while short sellers drool over a possible Valeant Pharmaceuticals ...
  13. Teva Expands Both Branded, Generics (TEVA, AGN)

    August 3, 2016
    Teva has purchased Allergan's generics business but will continue to focus on its specialized branded drugs.
  14. Pfizer Exits Brazil: Teva Is Suitor (PFE, TEVA)

    July 29, 2016
    Pfizer is planning to exit the Brazilian market as it puts its generic drug joint venture stake up for sale. Teva and Mylan ...
  15. Is Einhorn Investing in the Next Valeant Stock? (VRX)

    June 29, 2016
    Learn why famed hedge fund manager David Einhorn initiated a long position in Mylan despite regulatory concerns about the ...
  16. Why Teva Pharma Continues to Sell Assets (TEVA)

    June 28, 2016
    Teva is on an asset selling spree to fund its $40.5 billion acquisition of Allergan.
  17. Positive FDA Committee Vote on Vantrela Bodes Well for Remoxy

    June 10, 2016
    Here are the latest news related to the FDA approvals for three pain relievers.
  18. (VRX) Who are Valeant's Main Competitors?

    April 23, 2016
    Learn which companies Valeant is likely watching closely, since it is known for acquiring companies for their products rather ...
  19. The 5 Largest Middle East & Africa ETFs (MENA)

    April 16, 2016
    Learn about the five largest Middle Eastern and African equity ETFs. Explore the AUM, trading volume, expense ratio and dividend ...
  20. Allergan Now Trades Cheaper Than Its Standalone Value

    April 5, 2016
    Shibani Malhotra of Nomura thinks Allergan plc Ordinary Shares (NYSE: AGN) is compelling, despite treasury notice that threatens ...
  21. Why Lannett Cut Its Guidance for Fiscal 2016

    March 24, 2016
    Lannett (NYSE: LCI) has revised downward its guidance for the current fiscal year. Among other line item projections, the ...
  22. John Paulson's 5 Best Dividend Stocks (STAY, HOT)

    March 14, 2016
    Check out five of the top dividend-paying stocks that hedge fund manager John Paulson has recently recommended by investing ...
  23. William Blair & Company: Investment Manager Highlight

    March 12, 2016
    Learn about William Blair's service offering, executive leadership and holdings. Learn about the firm's areas of expertise ...
  24. How the New Allergan Plc Will Make Money

    January 14, 2016
    Allergan plc is not only enormous, it's about to more than double in size. Here's why and how.
  25. Teva Pharma Makes a $2.3 Billion Acquisition

    October 1, 2015
    Making good on its promise to chase acquisition opportunities, generic drugs specialist Teva Pharmaceutical Industries (NYSE: ...
  26. Teva Pharma to Acquire Allergan: Analysts Weigh In

    July 28, 2015
    Teva Pharmaceutical announced a definitive agreement to buy Allergan Inc. for $40.5 billion. What analysts are saying?
  27. The Pharmaceutical Feud: Mylan, Teva and Perrigo

    June 3, 2015
    Find out what Tipranks' analysts think about several pharmaceutical giants competing in the realm of mergers and acquisitions.
  28. Novo Nordisk Getting Its Trial By Fire

    August 8, 2013
    Novo Nordisk is facing more challenges than it has in a while, but the growth remains strong.
  29. Big Pharma Faces 'Pay For Delay' Lawsuits

    June 21, 2013
    Unless you follow the pharmaceutical and biotech sectors, it’s likely that you’ve never heard of pay to delay. Instead of ...
  30. Birth Control Subsidies Slashed: Will Big Pharma Take A Hit?

    March 6, 2012
    Several states have already slashed birth control subsidies. Learn how this will affect pharmaceutical stocks.
  31. 4 Double-Cross Buy Signs

    December 1, 2008
    Will the double crossover on MACD and Stochastic indicators trigger a move higher?
Trading Center